Aerie Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Vicente Anido
- Full Time Employees
- 376
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 4301 Emperor Blvd Ste 400 Durham NC United States of America 27703
- IPO Date
- Oct 25, 2013
- CIK
- 0001337553
- Website
- aeriepharma.com
- Similar Companies
- Business
- Aerie Pharmaceuticals, Inc. Aerie Pharmaceuticals, Inc. (AERI) operates as a clinical-stage ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of therapies for glaucoma, retinal diseases, dry eye, and other ocular conditions; its principal products include Rhopressa (netarsudil ophthalmic solution 0.02%), a Rho kinase inhibitor for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, and Rocklatan (netarsudil/latanoprost fixed-dose combination ophthalmic solution 0.02%/0.005%), a once-daily eye drop targeting the same indications. The company advances a pipeline encompassing AR-13503 and AR-1105 sustained-release implants for retinal diseases, alongside AR-15512, a Phase 3 candidate for dry eye disease signs and symptoms. Founded in 2005 and headquartered in Durham, North Carolina, Aerie maintains manufacturing and research facilities in the United States, with prior commercial operations extending to Europe via approvals for Rhokiinsa (netarsudil). In November 2022, Alcon Inc. completed its acquisition of Aerie Pharmaceuticals, Inc. for approximately $770 million in equity value plus debt assumption, fully integrating its glaucoma franchise, including Rhopressa and Rocklatan, into Alcon's ophthalmic pharmaceutical portfolio to leverage expanded global commercial infrastructure. This transaction followed Aerie's establishment of a GMP-validated PRINT technology manufacturing facility in Durham for clinical production of retinal implants and facility expansion to over 61,000 square feet in 2018, enhancing R&D capacity for sustained-release programs. Subsequent developments include Santen Pharmaceutical's 2021 global expansion of its licensing agreement for Rocklatan/Roclanda into Europe and additional regions, bolstering international market access as of 2025.
Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business
Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates
Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
Add These 4 Top-Ranked Liquid Stocks For Healthy Gains
5 Small Hidden Gems Flying High Despite Market's Bloodbath
5 Stocks to Bet on in an Innovation-Driven Drug Industry
Are Medical Stocks Lagging Aerie Pharmaceuticals (AERI) This Year?
AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI
Is Aerie Pharmaceuticals (AERI) Stock Outpacing Its Medical Peers This Year?
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, ECOM, PFS, LBAI
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AERI, ECOM, PFS, LBAI
Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
Is Aerie Pharmaceuticals (AERI) Outperforming Other Medical Stocks This Year?
Has Aerie Pharmaceuticals (AERI) Outpaced Other Medical Stocks This Year?
Why Aerie Pharmaceuticals Was Soaring So High This Week
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates ONEM, CCXI, AERI, SFT
Don't Look for Alcon's Acquisition to Boost Share Price in Short Term
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Aerie Pharmaceuticals, Inc. Buyout
AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders
SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.